Ind-Swift Labs gets USFDA EIR for Derabassi API facility

Mumbai: Ind-Swift Laboratories Limited has received the Establishment Inspection Report (EIR) from the USFDA, for the Surveillance GMP inspection of its API manufacturing facility located at Derabassi, Punjab.

"The USFDA inspection was conducted from 09th March 2020 to 13th March 2020. The EIR has been issued without any FORM 483 observations", Company added

This is the Sixth Successful USFDA inspection completed by the Company. IndSwift Supplies 15 APIs to its customers based in the U.S.

The APIs manufactured from the Derabassi Manufacturing facility are supplied across the world to over 70 countries covering more than 280 customers including all the major drug manufacturers across the Globe.

Ind-Swift Laboratories Ltd is a global manufacturer of APIs, Intermediates, and formulations (through group collaboration) headquartered in Chandigarh, India.

With regulated 6+ manufacturing sites in Punjab and Jammu, it caters to the API needs of regulated markets including USFDA, EDQM, PMDA, ANVISA, EU-GMP, KFDA, NMO, ANSM, Cofepris, TGA, WHO, ROW.

Read also: Dr Reddy's Labs gets USFDA inspection closure report for Srikakulam plant